DermTech, Inc. (DMTK)
Stock Price:
$11.60 USD
0.00 (0.00%)
Updated Jul 15, 2020 4:00 PM EDT - Market open
Key Info
| Market Cap |
172.92M |
| Revenue (ttm) |
4.33M |
| Net Income (ttm) |
-17.98M |
| Shares Out |
18.11M |
| EPS (ttm) |
-3.34 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 15, 2020 |
| Last Price |
$11.60 |
| Previous Close |
$11.60 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
- |
| Day's Range |
11.52 - 12.08 |
| Day's Volume |
0 |
| 52-Week Range |
4.52 - 21.70 |
More Stats
| Market Cap |
172.92M |
| Enterprise Value |
105.00M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
18.11M |
| Float |
3.73M |
| EPS (basic) |
-1.44 |
| EPS (diluted) |
-3.34 |
| FCF / Share |
-1.95 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
349,096 |
| Short Ratio |
1.90 |
| Short % of Float |
3.06% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
39.98 |
| PB Ratio |
3.37 |
| Revenue |
4.33M |
| Operating Income |
-19.21M |
| Net Income |
-17.98M |
| Free Cash Flow |
-25.51M |
| Net Cash |
67.92M |
| Net Cash / Share |
4.56 |
| Gross Margin |
1.39% |
| Operating Margin |
-444.08% |
| Profit Margin |
-484.50% |
| FCF Margin |
-589.72% |
| ROA |
-36.16% |
| ROE |
-76.46% |
| ROIC |
-2,069.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
24.0
Current: 11.60
High
24.0
Target: 24.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2016 |
|---|
| Revenue | 3.36 | 2.44 | - |
| Revenue Growth | 37.76% | - | - |
| Gross Profit | 0.06 | -0.19 | - |
| Operating Income | -17.61 | -8.56 | - |
| Net Income | -19.69 | -10.00 | - |
| Shares Outstanding | 7.01 | 4.41 | 3.75 |
| Earnings Per Share | -2.81 | -2.27 | - |
| Operating Cash Flow | -17.79 | -7.61 | - |
| Capital Expenditures | -0.21 | -0.01 | - |
| Free Cash Flow | -18.00 | -7.62 | - |
| Cash & Equivalents | 15.37 | 4.75 | 0.03 |
| Total Debt | - | 5.54 | 0.17 |
| Net Cash / Debt | 15.37 | -0.78 | -0.14 |
| Assets | 18.21 | 5.66 | 0.19 |
| Liabilities | 5.72 | 11.02 | 0.17 |
| Book Value | 12.49 | -5.36 | 0.02 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
DermTech, Inc. |
| Country |
United States |
| Employees |
60 |
| CEO |
John D. Dobak |
Stock Information
| Ticker Symbol |
DMTK |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: DMTK |
Description
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.